Araki, Kenji
Matsumoto, Nobuhiro
Togo, Kanae http://orcid.org/0000-0003-3964-4009
Yonemoto, Naohiro
Ohki, Emiko
Xu, Linghua
Hasegawa, Yoshiyuki
Inoue, Hirofumi
Yamashita, Sakiko
Miyazaki, Taiga
Funding for this research was provided by:
Pfizer Japan (Pfizer Japan, Pfizer Japan)
Article History
Received: 2 August 2022
Accepted: 8 February 2023
First Online: 16 February 2023
Declarations
:
: This study was approved by the ethics committee of University of Miyazaki (registration no.: 0-0845) and the opt-out consent process was granted. The study was conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects by Ministry of Education, Culture, Sports, Science and Technology (MEXT), and Ministry of Health, Labor and Welfare (MHLW).
: All authors agreed with the content and that all gave explicit consent to submit the final version to be published.
: Kenji Araki and Nobuhiro Matsumoto have received research funding from Pfizer.Kanae Togo, Naohiro Yonemoto, Emiko Ohki and Linghua Xu are employees of Pfizer Japan Inc. Taiga Miyazaki is consultant or advisor in Pfizer, Kyorin, and Asahi Kasei Pharma.Taiga Miyazaki is also a Speakers’ bureau in Pfizer, MSD, Astellas, Sumitomo Dainippon Pharma, Kyorin, GSK, Lilly, Meiji Seika Pharma, Novartis, Boehringer Ingelheim, and AstraZeneca. Taiga Miyazaki has also received research funding from Pfizer, Astellas, Toyama Chemical, Asahi Kasei Pharma, and MSD.